MPR
@eMPR
Followers
4K
Following
413
Media
1K
Statuses
22K
MPR provides daily drug news and industry-supported drug information & education. Download our drug reference and clinical tools app today!
New York
Joined August 2008
Episodic migraine treatment now available for pediatrics.
empr.com
The sBLA for the pediatric indication is supported by data from the randomized, double-blind, placebo-controlled, phase 3 SPACE trial.
0
0
0
Looking for a curated list of the top news and updates on pediatric rheumatology? Sign up for the Grand Roundup newsletter, delivered to your inbox bi-weekly.
0
0
0
New CDC director appears to be at odds with HHS Secretary Kennedy on issues such as vaccination and fluoridation of public water supplies.
0
0
0
A wearable, noninvasive device that evaluate cardiac timing intervals such as left ventricular ejection time, is given green light.
empr.com
The wearable, noninvasive CardioTag is designed to capture electrocardiogram, photoplethysmogram, and seismocardiogram signals, as well as heart rate and pulse rate.
0
0
0
AbbVie's Rinvoq shows promise in treating severe alopecia.
empr.com
The UP-AA clinical program includes 2 studies assessing the safety and efficacy of upadacitinib in adults and adolescent patients with severe alopecia areata.
0
0
0
New treatment approved for rare kidney diseases.
empr.com
Pegcetacoplan inhibits C3 activation by binding to C3 and its activation fragment C3b, thereby reducing C3 glomerular fragment deposition in patients with C3G and primary IC-MPGN.
0
0
0
RFK Jr. is weighing whether to remove the panel that decides what services insurance plans must cover.
0
0
0
The review period for a potentially new treatment for hot flashes has been given an extension of 90 days by the FDA.
empr.com
Elinzanetant is a dual neurokinin-1,3 (NK-1,3) receptor antagonist.
0
0
0
Looking for the latest respiratory infectious disease research, conference news, and guideline updates? Sign up for the Grand Roundup, our curated and specialized bi-weekly newsletter on clinical topics that matter most to you.
0
0
0
Doptelet approved for thrombocytopenia in pediatric patients with persistent or chronic immune thrombocytopenia who have had an insufficient response to a prior therapy.
empr.com
The approval was based on data from the randomized, double-blind, placebo-controlled phase 3b AVA-PED-301 trial.
0
0
0
🎧 Latest MPR Pod out now. This week:.🚢 Elevidys shipments paused;.🔹 FDA votes against Brexpiprazole for PTSD;.🔸 Rapiblyk now available;.😴 A pill for sleep apnea looks promising; and.🚬 JUUL is given green light to sell in the US.
0
0
0
Dr George Tidmarsh, who has led the development of 7 FDA-approved drugs and headed up several biopharma companies, has been appointed as the director of the Center for Drug Evaluation and Research.
empr.com
Tidmarsh's areas of expertise include pediatrics, pediatric oncology, and neonatology.
0
0
0
Could a pill be the future of sleep apnea treatment? New trial results show promise.
0
0
0
An FDA panel voted 10 to 1 against approving Otsuka and Lundbeck's combo treatment for PTSD.
empr.com
Brexpiprazole is an atypical antipsychotic approved under the brand name Rexulti.
0
0
0
President Trump's landmark bill will result in greater than 10 million people losing Medicaid by 2034.
0
0
0
In response to the FDA request, Sarepta issued a statement saying that they would continue to ship the product to ambulant DMD patients as there has been no new safety signals in this patient population.
0
0
0
FDA calls for pause to shipments of Sarepta's Elevidys gene therapy following third death.
1
0
0
Based on CBO figures, 7.6 million people will become uninsured by 2034 which would result in 94,802 preventable hospitalizations per year.
0
0
0
Searching for the latest news and research about COVID-19 and other emerging diseases? Sign up for the Grand Roundup, our curated newsletter to help you stay informed on clinical topics that matter most to you:
0
0
0